VILNIUS - Sanitas group, the owner of pharmaceutical plants in Lithuania, Poland and Slovakia, reported consolidated sales of 169.15 million litas (49 million euros) last year, 2.6 times more than in 2005, when the group did not include the Polish pharmaceutical plant Jelfa, which accounted for almost two-thirds of 2006's turnover.
Jelfa's sales came in at 101.37 million litas last year.
The sales of Sanitas alone shrank by 10 percent, year-on-year, to 32.34 million litas, while the sales of Slovak Hoechst-Biotika plant grew by 11.2 percent, to 30.25 million litas in the reporting period.
Sales in Poland accounted for 34 percent of consolidated 2006 sales. Sales in Russia comprised 14 percent, Latvia - 13 percent, Germany - 9 percent, Slovakia - 8 percent, Lithuania - 8 percent, other countries - 14 percent of total sales, Sanitas reported.
Sanitas, which is quoted on the Official List of the Vilnius Stock Exchange (VSE), posted 7.76 million litas in consolidated losses for the first eleven months of 2006.
The group sees full-year consolidated losses reaching some 9.2 million litas owing to hardships in Poland.
Sanitas is projecting a consolidated net profit of approximately 21.3 million litas for 2007.
The Kaunas-based company is 91 percent owned by the Lithuanian investment company Invalda, along with associated individuals, firms, and the investment funds Amber Trust II SCA and Citigroup Venture Capital International Jersey.
